Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy

The purpose of the present study was to longitudinally track changes of metabolite markers detectable by magnetic resonance spectroscopy (MRS) in subjects with mild cognitive impairment (MCI) and to analyze these changes with respect to the rate of cognitive decline and clinical disease progression. Fifteen subjects with MCI and 12 healthy elderly controls were investigated longitudinally (average follow-up period: 3.4 years) using absolute quantification of metabolites within the mid-parietal grey matter and the parietal white matter [N-acetylaspartate (NAA), myo-inositol, choline, creatine, glutamine)] Our main findings include that a longitudinal decline in cognitive function (particularly in memory function) within the MCI group was predicted by a decline in absolute concentrations of the metabolic markers NAA and creatine. This effect was mainly explained by a significant decrease of NAA and creatine in those MCI subjects who converted to Alzheimer's dementia (AD) during the follow-up period. No differences were found at baseline between MCI converters and stable subjects, indicating that at least in the present study MRS did provide a predictive discrimination between converters and stable subjects. Our findings support the use of MRS as a tool for objectively monitoring disease progression even during the earliest stages of AD.

[1]  Peter Schönknecht,et al.  Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. , 2005, The American journal of psychiatry.

[2]  F. Jessen,et al.  Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients , 2001, Neurology.

[3]  D. Auer,et al.  Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease , 2005, Neuroscience Letters.

[4]  P. Renshaw,et al.  Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[5]  F. Jessen,et al.  Treatment monitoring and response prediction with proton MR spectroscopy in AD , 2006, Neurology.

[6]  S. Chantal,et al.  Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease , 2004, Brain Research.

[7]  M. Essig,et al.  Parahippocampal volume deficits in subjects with aging-associated cognitive decline. , 2003, The American journal of psychiatry.

[8]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[9]  Kevin M Bradley,et al.  Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. , 2002, Brain : a journal of neurology.

[10]  Patrizia Mecocci,et al.  Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy , 2006, Neurobiology of Aging.

[11]  M. Viitanen,et al.  Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease , 2006, Neurology.

[12]  Clifford R. Jack,et al.  Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease , 2007, Neurobiology of Aging.

[13]  O Henriksen,et al.  In vivo quantitation of metabolite concentrations in the brain by means of proton MRS , 1995, NMR in biomedicine.

[14]  Roland Kreis,et al.  Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy , 1993, Magnetic resonance in medicine.

[15]  E. Sullivan,et al.  Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease , 2000, The Lancet.

[16]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[17]  E G Tangalos,et al.  Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease , 2000, Neurology.

[18]  J. Frahm,et al.  Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. , 1993, Radiology.

[19]  P Sachdev,et al.  Magnetic resonance spectroscopy in AD , 2001, Neurology.

[20]  S. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[21]  N. Butters,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery , 1994, Neurology.

[22]  Giuseppe Scotti,et al.  A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment , 2005, NeuroImage.

[23]  Clifford R Jack,et al.  1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease , 2002, Journal of the International Neuropsychological Society.

[24]  P. Sundgren,et al.  Magnetic resonance spectroscopy. , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[25]  N. Schuff,et al.  Headache and cerebral venous air embolism , 2007, Neurology.

[26]  U Senin,et al.  1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging , 2001, Neuroreport.

[27]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[28]  B. L. Miller,et al.  Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients , 2005, Neurology.

[29]  L R Schad,et al.  Quantitative magnetic resonance imaging and neuropsychological functions in dementia of the Alzheimer type , 1997, Psychological Medicine.

[30]  N. Fayed,et al.  Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. , 2005, The American journal of psychiatry.

[31]  C. Jack,et al.  Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. , 2003, AJNR. American journal of neuroradiology.